MedTrace Logo

Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases in NSCLC

NCT04912128 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2021-06-03

No results posted yet for this study

Summary

The purpose of this study is to determine whether stereotactic radiosurgery combination with Anlotinib could improve the efficacy and outcomes for non-small cell lung cancer with limited brain metastases.

Conditions

  • Stereotactic Body Radiation Therapy

Interventions

DRUG

Anlotinib

Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret. Stereotactic Radiosurgery Stereotactic Radiosurgery as the initial treatment of non small cell lung cancer patients with limited brain metastases

Sponsors & Collaborators

  • Huashan Hospital

    collaborator OTHER

  • Tianjin Medical University

    collaborator OTHER

  • Peking University Third Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-15
Primary Completion
2021-06-01
Completion
2021-06-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04912128 on ClinicalTrials.gov